{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33497556",
  "DateCompleted": {
    "Year": "2021",
    "Month": "02",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "02",
    "Day": "03"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1056/NEJMe2100736"
    ],
    "Journal": {
      "ISSN": "1533-4406",
      "JournalIssue": {
        "Volume": "384",
        "Issue": "2",
        "PubDate": {
          "Year": "2021",
          "Month": "Jan",
          "Day": "14"
        }
      },
      "Title": "The New England journal of medicine",
      "ISOAbbreviation": "N Engl J Med"
    },
    "ArticleTitle": "Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant.",
    "Pagination": {
      "StartPage": "e14",
      "MedlinePgn": "e14"
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Rubin",
        "ForeName": "Eric J",
        "Initials": "EJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Baden",
        "ForeName": "Lindsey R",
        "Initials": "LR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Abdool Karim",
        "ForeName": "Salim S",
        "Initials": "SS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Morrissey",
        "ForeName": "Stephen",
        "Initials": "S"
      }
    ],
    "PublicationTypeList": [
      "Editorial",
      "Interview"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "N Engl J Med",
    "NlmUniqueID": "0255562",
    "ISSNLinking": "0028-4793"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Neutralizing"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Azabicyclo Compounds"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Quinazolines"
    },
    {
      "RegistryNumber": "3QKI37EEHE",
      "NameOfSubstance": "remdesivir"
    },
    {
      "RegistryNumber": "415SHH325A",
      "NameOfSubstance": "Adenosine Monophosphate"
    },
    {
      "RegistryNumber": "7S5I7G3JQL",
      "NameOfSubstance": "Dexamethasone"
    },
    {
      "RegistryNumber": "F6XM2TN5A1",
      "NameOfSubstance": "XL647"
    },
    {
      "RegistryNumber": "OF5P57N2ZX",
      "NameOfSubstance": "Alanine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "analogs & derivatives",
        "therapeutic use"
      ],
      "DescriptorName": "Adenosine Monophosphate"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Africa"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Age Factors"
    },
    {
      "QualifierName": [
        "analogs & derivatives",
        "therapeutic use"
      ],
      "DescriptorName": "Alanine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Antibodies, Neutralizing"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Azabicyclo Compounds"
    },
    {
      "QualifierName": [
        "epidemiology",
        "prevention & control",
        "therapy",
        "transmission"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Testing"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "immunology"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Communicable Disease Control"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Dexamethasone"
    },
    {
      "QualifierName": [
        "prevention & control",
        "statistics & numerical data"
      ],
      "DescriptorName": "Disease Transmission, Infectious"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "organization & administration"
      ],
      "DescriptorName": "Immunization Programs"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Patient Acuity"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Quinazolines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology",
        "pathogenicity",
        "ultrastructure"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sequence Analysis, RNA"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "South Africa"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Virulence"
    }
  ]
}